Beta Bionics Statistics

Total Valuation

Beta Bionics has a market cap or net worth of $668.39 million. The enterprise value is $548.15 million.

Market Cap	668.39M
Enterprise Value	548.15M

Important Dates

The next estimated earnings date is Tuesday, May 6, 2025, before market open.

Earnings Date	May 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Beta Bionics has 42.86 million shares outstanding.

Current Share Class	42.86M
Shares Outstanding	42.86M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+23.74%
Owned by Insiders (%)	3.16%
Owned by Institutions (%)	13.24%
Float	41.34M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.00
Forward PS	7.45
PB Ratio	18.31
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	10.34
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.62, with a Debt / Equity ratio of 0.22.

Current Ratio	4.62
Quick Ratio	3.82
Debt / Equity	0.22
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-711.95

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-51.33%
Revenue Per Employee	$182,247
Profits Per Employee	-$190,708
Employee Count	291
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	19.89
Average Volume (20 Days)	338,391

Short Selling Information

The latest short interest is 945,109, so 2.21% of the outstanding shares have been sold short.

Short Interest	945,109
Short Previous Month	209,284
Short % of Shares Out	2.21%
Short % of Float	2.29%
Short Ratio (days to cover)	0.05

Income Statement

In the last 12 months, Beta Bionics had revenue of $53.03 million and -$55.50 million in losses. Loss per share was -$4.89.

Revenue	53.03M
Gross Profit	29.26M
Operating Income	-40.58M
Pretax Income	-55.50M
Net Income	-55.50M
EBITDA	-39.37M
EBIT	-40.58M
Loss Per Share	-$4.89

Full Income Statement

Balance Sheet

The company has $60.90 million in cash and $7.30 million in debt, giving a net cash position of $53.60 million or $1.25 per share.

Cash & Cash Equivalents	60.90M
Total Debt	7.30M
Net Cash	53.60M
Net Cash Per Share	$1.25
Equity (Book Value)	32.87M
Book Value Per Share	-34.35
Working Capital	64.68M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$40.34 million and capital expenditures -$3.15 million, giving a free cash flow of -$43.49 million.

Operating Cash Flow	-40.34M
Capital Expenditures	-3.15M
Free Cash Flow	-43.49M
FCF Per Share	-$1.01

Full Cash Flow Statement

Margins

Gross margin is 55.17%, with operating and profit margins of -76.52% and -104.64%.

Gross Margin	55.17%
Operating Margin	-76.52%
Pretax Margin	-104.64%
Profit Margin	-104.64%
EBITDA Margin	-74.24%
EBIT Margin	-76.52%
FCF Margin	n/a

Dividends & Yields

Beta Bionics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-9.22%
FCF Yield	-7.23%

Analyst Forecast

The average price target for Beta Bionics is $26.67, which is 71.02% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$26.67
Price Target Difference	71.02%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Beta Bionics has an Altman Z-Score of -4.06 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.06
Piotroski F-Score	1